Inhibrx Selects Genialis ResponderID™ for Clinical Optimization Study of INBRX-109

Machine Learning technology platform to be evaluated for potential use in predictive modeling for clinical development.

Genialis, a computational precision medicine company unraveling complex biology to find new ways to address disease, today announced it will work with Inhibrx in an effort to develop a predictive biomarker for INBRX-109 in solid tumors. Genialis will utilize its AI/ML clinical biomarker discovery platform, ResponderID™, to help Inhibrx identify features for potential patient stratification and model the underlying biologies that predict response to the drug candidate.

INBRX-109 is a precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody designed to exploit the tumor-biased cell death induced by DR5 activation. In January 2021, the FDA granted Fast Track designation to INBRX-109 for the treatment of patients with unresectable or metastatic conventional chondrosarcoma. In collaboration with clinical researchers and data scientists at Inhibrx, Genialis is using ResponderID™ to derive representative gene sets and model the complex biologies that govern response to DR5 agonism. This work incorporates numerous data sets from Inhibrx’s preclinical studies and clinical programs, the public domain, and Genialis’ proprietary ML-ready database. The goal is to improve resolution of patient stratification to accurately identify potential responders and understand patient outcomes.

Read the press release in its entirety here.

Coverage in Precision Oncology News
Coverage in BioWorld